XENE insider trading
NasdaqGM HealthcareXenon Pharmaceuticals Inc.: insider trade history from SEC Form 4 filings.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Company website: www.xenon-pharma.com
XENE insider activity at a glance
FilingIQ tracks 431 insider transactions for XENE in filings since Jan 7, 2015. The most recent transaction is dated Sep 30, 2026.
Across the full history, 55 open-market purchases
and 120 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on XENE insider trades is 57.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest XENE Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding XENE
Frequently asked
- How many insider trades does FilingIQ track for XENE?
- FilingIQ tracks 431 Form 4 insider transactions for XENE (Xenon Pharmaceuticals Inc.), covering filings from Jan 7, 2015 onwards. 6 of those are dated within the last 90 days.
- Are XENE insiders net buyers or net sellers?
- Across the full Form 4 history for XENE, 55 transactions (13%) were open-market purchases and 120 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does XENE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is XENE in?
- Xenon Pharmaceuticals Inc. (XENE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.36B.
Methodology & sources
Every XENE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.